Camurus' development projects address serious unmet medical needs over a range of therapeutic areas, including cancer, endocrinology, pain, metabolic disease and drug addiction. Our product pipeline represents a mix of in-house and partnered projects in different development phases.
The product is developed by Novartis with support from Camurus for treatment of acromegaly and neuroendocrine tumours and has several important advantages over current marketed products. CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus' proprietary FluidCrystal® injection depot technology.
CAM2029 comprises the active substance octreotide, which is a synthetic peptide analogue of the endogenous peptide hormon somatostatin. Somatostatin analogues (SSA) are today standard in the safe and effective symptomatic treatment of patients with acromegaly and neuroendocrine tumors (NETs). SSAs have in clinical trials demonstrated efficacy against tumors and is a treatment option for unresectable NETs. Current marketed SSA products include short acting octreotide (Sandostatin® from Novartis and generic versions), the market leading formulation octreotide LAR (Sandostatin® LAR® from Novartis), and two long-acting formulations of lanreotide (Somatuline® LA® and Somatuline® Autogel® from Ipsen).
CAM2029 is provided in a prefilled syringe equipped with a needle stick protection device. The product is conveniently administered subcutaneously , also by the patient itself, without any complicated reconstitution steps or conditioning requirements before use. Moreover, CAM2029 is compatible with autorinjector devices, which may further facilitate patient self-administration.
CAM2038 includes two long-acting subcutaneous buprenorphine products for maintenance treatment of opiod dependence, intended for administration once weekly (q1w) and once monthly (q4w). The products, based on Camurus' proprietary FluidCrystal® injection depot technology, are being developed to address several shortcomings of currently available drugs, for instance poor compliance, extensive misuse and diversion, and frequent relapse to abuse.
CAM2038 combines the known and well documented active substance buprenorphine with Camurus' proprietary FluidCrystal® injection depot technology. Because of the long-acting effect, CAM2038 needs to be administered only 12 or 52 times per year, which reduces the burden of daily administration as is the case with current medications (often health care personnel monitored administration, which is time consuming and costly for patients and society). CAM2038 will be administered in a controlled setting by healtcare personnel as a convenient subcutaneous injection, which cannot be misused, abused, or diverted to the illegal market.
CAM2038 will be available in several doses for weekly and monthly administration. This flexibility was developed to enable the product to be used during all phases of opioid addiction treatment, from treatment induction to stabilization and long-term maintenance therapy. The dose flexibility is also important to meet the patients' individual needs, depending on treatment phase, abuse history, and other factors. CAM2038 will be provided in prefilled syringes with a needle stick protection device. The products are small volume subcutaneous injections without need for reconstitution before use.
CAM2038 is a subcutaneous injection depot of buprenorphine for simple and safe administration by a prefilled syringe. Besides treatment of opiod dependence, CAM2038 once weekly (q1w) and once monthly (q4w) are developed for treatment of chronic pain. Initially, the products will be used to treat opioid experienced patients, but product variants for opioid naive patients are also being developed.
CAM2038 gives a fast onset of effect and a dose proportional extended exposure without the same risk for overdose and respiratory depression which is associated with full mu agonists such as morphine, fentanyl, etc. The product profile corresponds well with the target profile for chronic pain drug products and addresses a clear medical need to combine pain relief with a reduced risk of misuse and improved safety. The subcutaneous route of administration is expected to increase compliance and reduce the risks of incorrect use. Also when compared with transdermal opioid formulations, it's indicating that CAM2038 may be particularly well suited for chronic pain patients with a history of misuse. While chronic pain and substance abuse disorders often occur concurrently, these patients are particularly difficult to treat using existing opioid products.
Camurus' CAM2032 is a long-acting formulation of leuprolide which features both fast onset and prolonged release of leuprolide acetate. The product, which initially is developed for long term treatment of prostate cancer, is based on Camurus' proprietary FluidCrystal® injection depot technology and have been designed for simple and convenient administration, also by patients themselves, by a prefilled syringe with a thin needle and a needle stick protection device.
CAM2032 is developed for self-administration, which has the potential to increase flexibility for patients concurrently with reducing the burden of scheduling injections. The development of an auto-injector version is expected to further simplify handling and administration of CAM2032. Thanks to the product’s user-friendly design, CAM2032 does not require reconstitution or being kept at a special temperature prior to administration in a small-volume (0.2 or 0.4 mL) liquid with a thin 27 gauge needle. After injection, the lipid formulation is transformed into a liquid crystal gel matrix which slowly releases therapeutic levels of leuprolide over at least a month.
Compared with other injectable GnRH agonist products on the market, CAM2032 has several potential advantages, including its simple administration, small injection volume, thin needle and the possibility of self-administration by patients.
episil® oral liquid is a lipid-based fluid developed for the management and relief of pain associated with oral lesions of various aetiologies such as oral mucositis, a painful side effect of cancer therapies. After administration, and in contact with small quantities of saliva present in the oral cavity, the lipid mixture self-assembles to form a robust protective lipid membrane that strongly adheres to the oral mucosa, and soothes painful ulcerations.
episil® oral liquid is based on Camurus’ FluidCrystal® topical bioadhesive technology, and has been clinically proven to provide effective and rapid oral pain relief that lasts for up to 8 hours. episil® liquid helps patients to maintain their quality of life while undergoing cancer treatment.
For more information, see www.episil.net